{"id":13920,"date":"2013-08-06T01:30:00","date_gmt":"2013-08-05T23:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/nuova-normativa-di-farmacovigilanza-verso-gli-stati-uniti-d%c2%92europa\/"},"modified":"2013-08-06T01:30:00","modified_gmt":"2013-08-05T23:30:00","slug":"nuova-normativa-di-farmacovigilanza-verso-gli-stati-uniti-d%c2%92europa","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/nuova-normativa-di-farmacovigilanza-verso-gli-stati-uniti-d%c2%92europa\/","title":{"rendered":"New Pharmacovigilance legislation: towards the United States of Europe"},"content":{"rendered":"<p style=\"text-align: left; margin-bottom: 0pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; font-size: 11pt\">A year ago the new legislation came into force <a href=\"http:\/\/www.agenziafarmaco.gov.it\/it\/glossary\/term\/1454\" target=\"_blank\" rel=\"noopener\"><dfn><span style=\"color: #008800; text-decoration: none; text-underline: none\"><strong>Pharmacovigilance<\/strong><\/span><\/dfn><\/a> thanks to which the legal framework for the surveillance of medicinal products has been substantially modified, with rules aimed at strengthening the possibilities of identifying the &quot;signal&quot; and making the procedure that must be implemented to deal with all the drug safety issues.<\/p>\n<p><\/span><\/p>\n<p style=\"text-align: left; margin-bottom: 0pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; font-size: 11pt\">&quot;The European breath of <a href=\"http:\/\/www.agenziafarmaco.gov.it\/it\/glossary\/term\/1454\" target=\"_blank\" rel=\"noopener\"><dfn><span style=\"color: #008800; text-decoration: none; text-underline: none\"><strong>Pharmacovigilance<\/strong><\/span><\/dfn><\/a>, although already present in previous regulations, is increasingly accentuated - explains Giuseppe Pimpinella, Director of the Office <a href=\"http:\/\/www.agenziafarmaco.gov.it\/it\/glossary\/term\/1454\" target=\"_blank\" rel=\"noopener\"><dfn><span style=\"color: #008800; text-decoration: none; text-underline: none\"><strong>Pharmacovigilance<\/strong><\/span><\/dfn><\/a> of AIFA \u2013 The new directive is in fact focused on the sharing of tasks between the various Authorities: while before the sharing of activities was almost an optional exercise, more like a simple exchange of views, now the division of tasks is a true regulatory requirement is exactly&quot;.<\/p>\n<p><\/span><\/p>\n<p style=\"text-align: left; margin-bottom: 0pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; font-size: 11pt\">The new European Directive on <a href=\"http:\/\/www.agenziafarmaco.gov.it\/it\/glossary\/term\/1454\" target=\"_blank\" rel=\"noopener\"><dfn><span style=\"color: #008800; text-decoration: none; text-underline: none\"><strong>pharmacovigilance<\/strong><\/span><\/dfn><\/a> (DE 2010\/84\/EC) introduced many important changes. More transparency, reporting directly from citizens and broadening the definition of <a href=\"http:\/\/www.agenziafarmaco.gov.it\/it\/glossary\/term\/1475\" target=\"_blank\" rel=\"noopener\"><dfn><span style=\"color: #008800; text-decoration: none; text-underline: none\"><strong>adverse reaction<\/strong><\/span><\/dfn><\/a>, including those from therapeutic error and drug abuse.<\/p>\n<p><\/span><\/p>\n<p style=\"text-align: left\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; font-size: 11pt\">\u201cThe general strategic objectives of the new legislation \u2013 underlined Dr. Pimpinella \u2013 tend to ensure the greatest transparency, speed and effectiveness of the circulation of information on suspected adverse drug reactions (ADRs) and to better establish each role\u201d.<\/p>\n<p><\/span><\/p>\n<p style=\"text-align: left\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; font-size: 11pt\">One of the main points is the enhancement of the &quot;shared work&quot;: the evaluation carried out by each Member State is made available to all the others. Currently, for example, each Member State is entrusted with the safety assessments of different molecules, to then share the final results.<\/p>\n<p><\/span><\/p>\n<p style=\"text-align: left; margin-bottom: 0pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; font-size: 11pt\">\u201cNow the Member States have divided the medicinal specialties by <a href=\"http:\/\/www.agenziafarmaco.gov.it\/it\/glossary\/term\/1471\" target=\"_blank\" rel=\"noopener\"><dfn><span","protected":false},"excerpt":{"rendered":"<p>Un anno fa &egrave; entrata in vigore la nuova normativa di Farmacovigilanza grazie alla quale &egrave; stato modificato in modo sostanziale il quadro giuridico per la sorveglianza dei medicinali, con regole tese a rafforzare le possibilit&agrave; di identificazione del &ldquo;segnale&rdquo; e rendere pi&ugrave; preciso e veloce l&rsquo;iter che deve essere attuato per far fronte a &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13920"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13920\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}